Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Opthea Limited Sponsored ADR ( (OPT) ) is now available.
On January 28, 2025, Opthea Limited hosted an Investor Day in New York City, highlighting its product candidate sozinibercept, which is poised to be the first significant breakthrough in wet AMD treatment in two decades. The event underscored the substantial market opportunity for sozinibercept, which has shown superior visual outcomes in trials and could fill the unmet needs of patients experiencing vision loss despite existing treatments. The company anticipates pivotal trial results in 2025, with plans for U.S. commercial readiness, potentially impacting its market positioning and stakeholder interests.
More about Opthea Limited Sponsored ADR
Opthea Limited operates in the biopharmaceutical industry, focusing on developing therapies for eye diseases. The company is known for its innovative approach, particularly with its product candidate sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor aimed at treating wet age-related macular degeneration (AMD) in combination with standard anti-VEGF-A therapies.
YTD Price Performance: 29.44%
Average Trading Volume: 25,288
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $752.8M
See more insights into OPT stock on TipRanks’ Stock Analysis page.
